Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study of INOpulse® Inhaled Nitric Oxide Therapy for COVID-19
Stock Information for Bellerophon Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.